Today's Rundown No sleep, exiled mattresses, cleared bank accounts: Getting deals done at JPM Incyte pays $750M upfront for rights to MorphoSys cancer drug Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug JetBlue, but for biopharma: Borisy's EQRx nabs $200M, takes aim at drug prices Axsome picks up Pfizer's phase 3 fibromyalgia castoff As the biotech world makes San Francisco home for the week, Janssen has longer-term plans PPD sets out $1B IPO plans as it launches new China labs Featured Story | | | Monday, January 13, 2020 SAN FRANCISCO—We're always looking to ask the big questions at FierceBiotech, and, at this year's J.P. Morgan Healthcare Conference, we're asking: Where do all the orphaned mattresses go? Stick with us; it's a story of dealmaking madness at the biggest biopharma conference of the year. |
|
|---|
|
| Thank you to Rho for sponsoring this year's JPM 2020 coverage. |
Top Stories Monday, January 13, 2020 Incyte is set to pay MorphoSys $750 million upfront for rights to anti-CD19 antibody tafasitamab. The licensing deal, which features a $150 million equity investment and up to $1.1 billion in milestones, gives Incyte a big stake in a near-approval asset that achieved CAR-T-like efficacy in lymphoma patients. Monday, January 13, 2020 Biogen has placed another bet on Alzheimer’s disease R&D, paying Pfizer $75 million upfront for an early-phase prospect. The candidate, PF-05251749, came through tests in healthy volunteers at Pfizer before getting derailed by the Big Pharma’s retreat from neuroscience R&D in 2018. Sunday, January 12, 2020 SAN FRANCISCO—It's not news: Over time, biopharma companies have raised the price of new medicines ever higher—simply because they can, says veteran biotech investor Alexis Borisy. Now, he’s throwing a wrench in the system with a new kind of biotech company, one that will “reshape the industry” by introducing new medicines at “radically lower” prices. Monday, January 13, 2020 Axsome Therapeutics has licensed a fibromyalgia candidate more than a decade after Pfizer dropped it in light of clinical data. The deal gives Axsome the chance to resurrect a drug that beat placebo in phase 3 but nonetheless fell by the wayside at Pfizer. Monday, January 13, 2020 As the annual J.P. Morgan Healthcare Conference kicks off in San Francisco this week, Janssen has unveiled plans to double down on its own long-term presence in the area. Monday, January 13, 2020 No, that headline is not in error: The folks over at Renaissance Capital see private-cum-public-cum-private-cum-public CRO PPD putting down a very conservative $100 million IPO attempt, but it could raise a cool $1 billion. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|---|
|
Resources Sponsored by: DocuSign A digital transformation is taking place in the life sciences industry, from research laboratories to manufacturing facilities. But there has always been a gap in these technologies. Download the whitepaper to learn how this challenge was addressed. Sponsored by: DocuSign This paper discusses some of the challenges that the GDPR will introduce, with a particular focus on its requirements for obtaining verifiable, unambiguous consent. Sponsored by: DocuSign Download this paper to learn how you can fully digitize all paper processes. By doing so, you will see shorter cycle times, reduced development costs, and greater customer satisfaction. Sponsored by: Benchling As emerging modalities transform the needs of life science R&D, how can biotech and pharma companies use modern software approaches to increase productivity and reach breakthroughs faster? Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: ICON Clinical Research Ltd The beginning of this digital transformation is well underway and is likely to accelerate. Read our white paper, “Digital Disruption in Biopharma: How Digital Transformation can reverse declining ROI on R&D,” to learn more. Sponsored by: snapIoT, Inc. Download this white paper and read the expert feedback that snapIoT has gathered from industry thought leaders on the evolution, evaluation, and use of telemedicine solutions in clinical trials. Sponsored by: EVERSANA How are your launch strategies can convert “innovation” into value for patients? Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: Outer Edge Technology, LLC Why companies leverage the expertize of industry focused cloud service providers to design and build quality systems and facilitate the FDA Validation of Mission Critical Apps in the Cloud. Sponsored by: Colorcon Learn more: Best practices for defending supply chain security and compliance by efficiently managing product authentication. Sponsored by: Metabolon Small or emerging pharmaceutical and biotech companies pursuing novel molecules and targets have two important goals: achieve clinical success and attract new rounds of funding. While there’s never a guarantee of either, certain actions can influence the outcome in your favor. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. Asia-Pacific Healthcare Compliance Certificate Program March 9-12, 2020 11th Annual SCOPE Summit: Summit for Clinical Ops Executives February 18-21, 2020 | Orlando, FL BIO International Convention June 8-11, 2020 | San Diego, CA Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. Middle East Healthcare Compliance Certificate Program March 23-26, 2020 | 